Lucentis ranibizumab: Phase IIIb start

DNA will begin by year end the open-label, U.S. Phase IIIb SAILOR trial in about 5,000 patients to evaluate once-monthly 0.3 and 0.5 mg Lucentis for 3 months. Data from the Phase III ANCHOR trial to t...